Perrine SCHNELLER

Ms. Perrine SCHNELLER

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PSPerrine SCHNELLER
Perrine SCHNELLER
Charlotte COLLETCharlotte COLLET
Charlotte COLLET
QBQuentin Béen
Quentin Béen
PRPaul Rocchi
Paul Rocchi
FLFrancois Lux
Francois Lux
JDJoël Daouk
Joël Daouk
Cerenkov-induced photodynamic therapy (CR-PDT) with the use of Gallium-68 (68Ga) as an unsealed radioactive source has been proposed as an alternative strategy to X-ray-induced photodynamic therapy (X-PDT). This new strategy still aims to produce a photodynamic effect with the use of nanoparticles, namely, AGuIX. Recently, we replaced Gd from the AGuIX@ platform with Terbium (Tb) as a nanoscintillator and added 5-(4-carboxyphenyl succinimide ester)-10,15,20-triphenylporphyrin (P1) as a photosensitizer (referred to as AGuIX@Tb-P1). Although Cerenkov luminescence from 68Ga positrons is involved in nanoscintillator and photosensitizer activation, the cytotoxic effect obtained by PDT remains controversial. Herein, we tested whether free 68Ga could substitute X-rays of X-PDT to obtain a cytotoxic phototherapeutic effect. Results were compared with those obtained with AGuIX@Gd-P1 nanoparticles. We showed, by Monte Carlo simulations, the contribution of Tb scintillation in P1 activation by an energy transfer between Tb and P1 after Cerenkov radiation, compared to the Gd-based nanoparticles. We confirmed the involvement of the type II PDT reaction during 68Ga-mediated Cerenkov luminescence, id est, the transfer of photon to AGuIX@Tb-P1 which, in turn, generated P1-mediated singlet oxygen. The effect of 68Ga on cell survival was studied by clonogenic assays using human glioblastoma U-251 MG cells. Exposure of pre-treated cells with AGuIX@Tb-P1 to 68Ga resulted in the decrease in cell clone formation, unlike AGuIX@Gd-P1. We conclude that CR-PDT could be an alternative of X-PDT.

17 April 2026 in STAR Protocols
Verified
Journal Article
Open access
PSPerrine SCHNELLER
Perrine SCHNELLER
JPJulien PIERSON
Julien PIERSON
JDJoël Daouk
Joël Daouk
FRFabien Rech
Fabien Rech
MDMatthieu Doyen
Matthieu Doyen
Muriel BARBERI-HEYOBMuriel BARBERI-HEYOB
Muriel BARBERI-HEYOB
We present a protocol to develop a syngeneic surgical glioblastoma model using F98 cells in Fischer F344 rats. This model recapitulates tumor growth, surgical resection, and recurrence observed in patients. We describe procedures for F98 cell preparation, stereotactic implantation, MRI-guided tumor resection, and longitudinal MRI monitoring. This protocol provides a clinically relevant platform to investigate post-resection tumor recurrence and evaluate therapeutic strategies targeting residual disease.